NAT2 slow acetylator genotype/phenotype was suggested to predispose to SMX hypersensitivity in non-HIV/AIDS individuals [25,26], while no such associations were observed in HIV/AIDS patients in several studies [27-29], possibly owing to reduced activities of liver drug metabolizing enzymes during HIV infection. Here, NAT2 is linked to AIDS.